Summary of Recommendation Statements  by unknown
Summary of Recommendation Statements
Kidney International Supplements (2012) 2, 283–287; doi:10.1038/kisup.2012.41
Chapter 1: Diagnosis and evaluation of anemia in CKD
TESTING FOR ANEMIA
Frequency of testing for anemia
1.1.1: For CKD patients without anemia (as defined below in Recommendation 1.2.1 for adults and Recommendation
1.2.2 for children), measure Hb concentration when clinically indicated and (Not Graded):
K at least annually in patients with CKD 3
K at least twice per year in patients with CKD 4–5ND
K at least every 3 months in patients with CKD 5HD and CKD 5PD
1.1.2: For CKD patients with anemia not being treated with an ESA, measure Hb concentration when clinically indicated
and (Not Graded):
K at least every 3 months in patients with CKD 3–5ND and CKD 5PD
K at least monthly in patients with CKD 5HD
[See Recommendations 3.12.1–3.12.3 for measurement of Hb concentration in patients being treated with
ESA.]
Diagnosis of anemia
1.2.1: Diagnose anemia in adults and children 415 years with CKD when the Hb concentration iso13.0 g/dl (o130 g/l)
in males and o12.0 g/dl (o120 g/l) in females. (Not Graded)
1.2.2: Diagnose anemia in children with CKD if Hb concentration iso11.0 g/dl (o110 g/l) in children 0.5–5 years,o11.5
g/dl (115 g/l) in children 5–12 years, and o12.0 g/dl (120 g/l) in children 12–15 years. (Not Graded)
Investigation of anemia
1.3: In patients with CKD and anemia (regardless of age and CKD stage), include the following tests in initial evaluation
of the anemia (Not Graded):
K Complete blood count (CBC), which should include Hb concentration, red cell indices, white blood cell count
and differential, and platelet count
K Absolute reticulocyte count
K Serum ferritin level
K Serum transferrin saturation (TSAT)
K Serum vitamin B12 and folate levels
Chapter 2: Use of iron to treat anemia in CKD
TREATMENT WITH IRON AGENTS
2.1.1: When prescribing iron therapy, balance the potential benefits of avoiding or minimizing blood transfusions, ESA
therapy, and anemia-related symptoms against the risks of harm in individual patients (e.g., anaphylactoid and
other acute reactions, unknown long-term risks). (Not Graded)
2.1.2: For adult CKD patients with anemia not on iron or ESA therapy we suggest a trial of IV iron (or in CKD ND
patients alternatively a 1–3 month trial of oral iron therapy) if (2C):
K an increase in Hb concentration without starting ESA treatment is desired* and
K TSAT is r30% and ferritin is r500 ng/ml (r500 mg/l)
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*Based on patient symptoms and overall clinical goals, including avoidance of transfusion, improvement in anemia-related symptoms, and after exclusion of
active infection.
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2.1.3: For adult CKD patients on ESA therapy who are not receiving iron supplementation, we suggest a trial of IV iron
(or in CKD ND patients alternatively a 1–3 month trial of oral iron therapy) if (2C):
K an increase in Hb concentration** or a decrease in ESA dose is desired*** and
K TSAT is r30% and ferritin is r500 ng/ml (r500 mg/l)
2.1.4: For CKD ND patients who require iron supplementation, select the route of iron administration based on the
severity of iron deficiency, availability of venous access, response to prior oral iron therapy, side effects with prior
oral or IV iron therapy, patient compliance, and cost. (Not Graded)
2.1.5: Guide subsequent iron administration in CKD patients based on Hb responses to recent iron therapy,
as well as ongoing blood losses, iron status tests (TSAT and ferritin), Hb concentration, ESA responsiveness
and ESA dose in ESA treated patients, trends in each parameter, and the patient’s clinical status.
(Not Graded)
2.1.6: For all pediatric CKD patients with anemia not on iron or ESA therapy, we recommend oral iron (or IV iron in
CKD HD patients) administration when TSAT is r20% and ferritin is r100 ng/ml (r100 lg/l). (1D)
2.1.7: For all pediatric CKD patients on ESA therapy who are not receiving iron supplementation, we recommend oral
iron (or IV iron in CKD HD patients) administration to maintain TSAT 420% and ferritin 4100 ng/ml (4100 lg/
l). (1D)
IRON STATUS EVALUATION
2.2.1: Evaluate iron status (TSAT and ferritin) at least every 3 months during ESA therapy, including the decision to start
or continue iron therapy. (Not Graded)
2.2.2: Test iron status (TSAT and ferritin) more frequently when initiating or increasing ESA dose, when there is blood
loss, when monitoring response after a course of IV iron, and in other circumstances where iron stores may become
depleted. (Not Graded)
CAUTIONS REGARDING IRON THERAPY
2.3: When the initial dose of IV iron dextran is administered, we recommend (1B) and when the initial dose of IV non-
dextran iron is administered, we suggest (2C) that patients be monitored for 60 minutes after the infusion, and that
resuscitative facilities (including medications) and personnel trained to evaluate and treat serious adverse reactions
be available.
Iron during infection
2.4: Avoid administering IV iron to patients with active systemic infections. (Not Graded)
Chapter 3: Use of ESAs and other agents to treat
anemia in CKD
ESA INITIATION
3.1: Address all correctable causes of anemia (including iron deficiency and inflammatory states) prior to initiation of
ESA therapy. (Not Graded)
3.2: In initiating and maintaining ESA therapy, we recommend balancing the potential benefits of reducing blood
transfusions and anemia-related symptoms against the risks of harm in individual patients (e.g., stroke, vascular
access loss, hypertension). (1B)
**Consistent with Recommendations #3.4.2 and 3.4.3.
***Based on patient symptoms and overall clinical goals including avoidance of transfusion and improvement in anemia-related symptoms, and after exclusion
of active infection and other causes of ESA hyporesponsiveness.
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3.3: We recommend using ESA therapy with great caution, if at all, in CKD patients with active malignancy—in
particular when cure is the anticipated outcome—(1B), a history of stroke (1B), or a history of malignancy (2C).
3.4.1: For adult CKD ND patients with Hb concentration Z10.0 g/dl (Z100 g/l), we suggest that ESA therapy not be
initiated. (2D)
3.4.2: For adult CKD ND patients with Hb concentration o10.0 g/dl (o100 g/l) we suggest that the decision whether to
initiate ESA therapy be individualized based on the rate of fall of Hb concentration, prior response to iron therapy,
the risk of needing a transfusion, the risks related to ESA therapy and the presence of symptoms attributable to
anemia. (2C)
3.4.3: For adult CKD 5D patients, we suggest that ESA therapy be used to avoid having the Hb concentration fall below
9.0 g/dl (90 g/l) by starting ESA therapy when the hemoglobin is between 9.0–10.0 g/dl (90–100 g/l). (2B)
3.4.4: Individualization of therapy is reasonable as some patients may have improvements in quality of life at higher Hb
concentration and ESA therapy may be started above 10.0 g/dl (100 g/l). (Not Graded)
3.4.5: For all pediatric CKD patients, we suggest that the selection of Hb concentration at which ESA therapy is initiated
in the individual patient includes consideration of potential benefits (e.g., improvement in quality of life, school
attendance/performance, and avoidance of transfusion) and potential harms. (2D)
ESA MAINTENANCE THERAPY
3.5.1: In general, we suggest that ESAs not be used to maintain Hb concentration above 11.5 g/dl (115 g/l) in adult
patients with CKD. (2C)
3.5.2: Individualization of therapy will be necessary as some patients may have improvements in quality of life at Hb
concentration above 11.5 g/dl (115 g/l) and will be prepared to accept the risks. (Not Graded)
3.6: In all adult patients, we recommend that ESAs not be used to intentionally increase the Hb concentration above
13 g/dl (130 g/l). (1A)
3.7: In all pediatric CKD patients receiving ESA therapy, we suggest that the selected Hb concentration be in the range of
11.0 to 12.0 g/dl (110 to 120 g/l). (2D)
ESA DOSING
3.8.1: We recommend determining the initial ESA dose using the patient’s Hb concentration, body weight, and clinical
circumstances. (1D)
3.8.2: We recommend that ESA dose adjustments be made based on the patient’s Hb concentration, rate of change in Hb
concentration, current ESA dose and clinical circumstances. (1B)
3.8.3: We suggest decreasing ESA dose in preference to withholding ESA when a downward adjustment of Hb
concentration is needed. (2C)
3.8.4: Re-evaluate ESA dose if (Not Graded):
K The patient suffers an ESA-related adverse event
K The patient has an acute or progressive illness that may cause ESA hyporesponsiveness (See Recommendations
3.13.1–3.13.2)
ESA ADMINISTRATION
3.9.1: For CKD 5HD patients and those on hemofiltration or hemodiafiltration therapy, we suggest either intravenous or
subcutaneous administration of ESA. (2C)
3.9.2: For CKD ND and CKD 5PD patients, we suggest subcutaneous administration of ESA. (2C)
Frequency of administration
3.10: We suggest determining the frequency of ESA administration based on CKD stage, treatment setting, efficacy
considerations, patient tolerance and preference, and type of ESA. (2C)
TYPE OF ESA
3.11.1: We recommend choosing an ESA based on the balance of pharmacodynamics, safety information, clinical outcome
data, costs, and availability. (1D)
3.11.2: We suggest using only ESAs that have been approved by an independent regulatory agency. Specifically for ‘copy’
versions of ESAs, true biosimilar products should be used. (2D)
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EVALUATING AND CORRECTING PERSISTENT FAILURE TO REACH OR MAINTAIN INTENDED
HEMOGLOBIN CONCENTRATION
Frequency of monitoring
3.12.1: During the initiation phase of ESA therapy, measure Hb concentration at least monthly. (Not Graded)
3.12.2: For CKD ND patients, during the maintenance phase of ESA therapy measure Hb concentration at least every 3
months. (Not Graded)
3.12.3: For CKD 5D patients, during the maintenance phase of ESA therapy measure Hb concentration at least monthly.
(Not Graded)
Initial ESA hyporesponsiveness
3.13.1: Classify patients as having ESA hyporesponsiveness if they have no increase in Hb concentration from baseline
after the first month of ESA treatment on appropriate weight-based dosing. (Not Graded)
3.13.2: In patients with ESA hyporesponsiveness, we suggest avoiding repeated escalations in ESA dose beyond double the
initial weight-based dose. (2D)
Subsequent ESA hyporesponsiveness
3.14.1: Classify patients as having acquired ESA hyporesponsiveness if after treatment with stable doses of ESA, they
require 2 increases in ESA doses up to 50% beyond the dose at which they had been stable in an effort to maintain
a stable Hb concentration. (Not Graded)
3.14.2: In patients with acquired ESA hyporesponsiveness, we suggest avoiding repeated escalations in ESA dose beyond
double the dose at which they had been stable. (2D)
Management of poor ESA responsiveness
3.15.1: Evaluate patients with either initial or acquired ESA hyporesponsiveness and treat for specific causes of poor ESA
response. (Not Graded)
3.15.2: For patients who remain hyporesponsive despite correcting treatable causes, we suggest individualization of
therapy, accounting for relative risks and benefits of (2D):
K decline in Hb concentration
K continuing ESA, if needed to maintain Hb concentration, with due consideration of the doses required, and
K blood transfusions
ADJUVANT THERAPIES
3.16.1: We recommend not using androgens as an adjuvant to ESA treatment. (1B)
3.16.2: We suggest not using adjuvants to ESA treatment including vitamin C, vitamin D, vitamin E, folic acid,
L-carnitine, and pentoxifylline. (2D)
EVALUATION FOR PURE RED CELL APLASIA (PRCA)
3.17.1: Investigate for possible antibody-mediated PRCA when a patient receiving ESA therapy for more than 8 weeks
develops the following (Not Graded):
K Sudden rapid decrease in Hb concentration at the rate of 0.5 to 1.0 g/dl (5 to 10 g/l) per week OR requirement
of transfusions at the rate of approximately 1 to 2 per week, AND
K Normal platelet and white cell counts, AND
K Absolute reticulocyte count less than 10,000/ml
3.17.2: We recommend that ESA therapy be stopped in patients who develop antibody-mediated PRCA. (1A)
3.17.3: We recommend peginesatide be used to treat patients with antibody-mediated PRCA. (1B)
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Chapter 4: Red cell transfusion to treat anemia in CKD
USE OF RED CELL TRANSFUSION IN CHRONIC ANEMIA
4.1.1: When managing chronic anemia, we recommend avoiding, when possible, red cell transfusions to minimize the
general risks related to their use. (1B)
4.1.2: In patients eligible for organ transplantation, we specifically recommend avoiding, when possible, red cell
transfusions to minimize the risk of allosensitization. (1C)
4.1.3: When managing chronic anemia, we suggest that the benefits of red cell transfusions may outweigh the risks in
patients in whom (2C):
K ESA therapy is ineffective (e.g., hemoglobinopathies, bone marrow failure, ESA resistance)
K The risks of ESA therapy may outweigh its benefits (e.g., previous or current malignancy, previous stroke)
4.1.4: We suggest that the decision to transfuse a CKD patient with non-acute anemia should not be based on any
arbitrary Hb threshold, but should be determined by the occurrence of symptoms caused by anemia. (2C)
URGENT TREATMENT OF ANEMIA
4.2: In certain acute clinical situations, we suggest patients are transfused when the benefits of red cell transfusions
outweigh the risks; these include (2C):
K When rapid correction of anemia is required to stabilize the patient’s condition (e.g., acute hemorrhage, unstable
coronary artery disease)
K When rapid pre-operative Hb correction is required
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